Adhera Therapeutics Stock Current Valuation
Valuation analysis of Adhera Therapeutics helps investors to measure Adhera Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Adhera Therapeutics Company Current Valuation Analysis
Adhera Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Adhera Therapeutics Current Valuation | 10.55 M |
Most of Adhera Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Adhera Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Adhera Therapeutics has a Current Valuation of 10.55 M. This is 99.93% lower than that of the Biotechnology sector and 99.77% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.94% higher than that of the company.
Adhera Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Adhera Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Adhera Therapeutics could also be used in its relative valuation, which is a method of valuing Adhera Therapeutics by comparing valuation metrics of similar companies.Adhera Therapeutics is currently under evaluation in current valuation category among its peers.
Adhera Fundamentals
| Return On Asset | -4.48 | ||||
| Current Valuation | 10.55 M | ||||
| Shares Outstanding | 3.16 M | ||||
| Shares Owned By Insiders | 21.87 % | ||||
| Number Of Shares Shorted | 2.05 K | ||||
| Price To Earning | (125.83) X | ||||
| Price To Sales | 8.23 X | ||||
| Gross Profit | (157 K) | ||||
| EBITDA | (4.92 M) | ||||
| Net Income | (6.35 M) | ||||
| Cash And Equivalents | 849 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 7.35 M | ||||
| Debt To Equity | 56.30 % | ||||
| Current Ratio | 0.05 X | ||||
| Book Value Per Share | (6.90) X | ||||
| Cash Flow From Operations | (665 K) | ||||
| Short Ratio | 3.24 X | ||||
| Earnings Per Share | (0.52) X | ||||
| Number Of Employees | 12 | ||||
| Beta | -0.14 | ||||
| Market Capitalization | 2.18 M | ||||
| Total Asset | 196 K | ||||
| Retained Earnings | (42.43 M) | ||||
| Working Capital | 16.49 M | ||||
| Current Asset | 20.36 M | ||||
| Current Liabilities | 3.88 M | ||||
| Net Asset | 196 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in Adhera Pink Sheet
If you are still planning to invest in Adhera Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Adhera Therapeutics' history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |